Referent:innen

Markus Roucka

Markus Roucka

VelaLabs

Dr. Andreas Nechansky

Dr. Andreas Nechansky

VelaLabs

Markus Haberger

Markus Haberger

Roche Diagnostics

Christian Mayer

Christian Mayer

AGES

Dr. Andrea Hawe

Dr. Andrea Hawe

Coriolis Pharma Research

Dr. Ghazaleh Gouya

Dr. Ghazaleh Gouya

Gouya Insights

All times mentioned are CEST.

Zielsetzung

At the end of this course, participants will have a comprehensive understanding of monoclonal antibodies (mAbs).

From the early development process, through upstream and downstream manufacturing, to different analytical approaches, clinical trials and stability studies.

The course is designed to ensure that participants not only understand the theoretical underpinnings of mAb development, but also the practical and regulatory challenges that must be overcome to bring a therapeutic antibody from the laboratory to the clinic and ultimately to the market.

Hintergrund

Monoclonal antibodies (mAbs) are increasingly becoming a cornerstone of therapeutic strategies in a wide range of diseases, including oncology, rheumatology and infectious diseases. Their ability to target specific antigens with high precision makes them critical tools in the fight against complex diseases. The global market for monoclonal antibodies is expanding not only because of their efficacy but also because of technological advances in genetic engineering and bioprocessing.

The development of monoclonal antibodies involves a sophisticated and multidisciplinary approach that integrates the fields of molecular biology, genetic engineering, immunology and pharmacology. The complexity of the development process is compounded by the stringent requirements imposed by regulatory authorities to ensure the safety, efficacy and quality of these biopharmaceuticals before they reach the market.

Guidelines from regulatory agencies such as the US Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) provide structured pathways and requirements for the development and approval of monoclonal antibodies. These guidelines include detailed criteria for the manufacturing process, preclinical and clinical testing and submission of regulatory dossiers.

Given the rigorous and detailed nature of these guidelines, professionals involved in mAb development must have a deep understanding of both the scientific and regulatory landscape. It is essential that these professionals are familiar with critical guidelines such as ICH Q6B, which details test procedures and acceptance criteria for biotechnology and biological products, or ICH Q8(R2), which provides guidance on pharmaceutical development.

Zielgruppe

The programme is aimed at those working in research, clinical trials and anyone interested in developing monoclonal antibodies. By targeting this wide range of professionals, the training aims to create a knowledgeable and skilled workforce capable of advancing the field of monoclonal antibodies from the research phase through to clinical use and successful market entry.

Technical Requirements

We use WebEx for our live online training courses and webinars. At https://www.gmp-compliance.org/training/online-training-technical-information you will find all the information you need to participate in our trainings and you can check if your system meets the necessary requirements to participate. If the installation of browser extensions is not possible due to your rights in the IT system, please contact your IT department. WebEx is a standard nowadays and the necessary installation is fast and easy.

The presentations will be made available to you prior to the Live Online Training as PDF files. After the event, you will automatically receive your certificate of participation.

Programm

Monoclonal Antibodies - From Concept to Approval - Live Online Training

Gesamtes Programm als PDF herunterladen

World of mAbs: Introduction and Overview – From Idea to Product
  • What are monoclonal antibodies (mAbs)?
  • Conception to market – developing effective mAbs
  • Areas of application: therapeutic applications, diagnostics, Research
Analytical Concept for Fc and Fab
  • Antibody structures: Fc and Fab Analysis
  • Ligand Binding Assay (LBA) and other techniques
  • Bioassay Validation
Production Processes of mAbs: From Upstream to Downstream
  • Techniques and Technologies
  • Optimizing expression: techniques for enhancing yield and quality
  • Challenges and solutions in scale-up for commercial production
Production processes of mAbs: Choosing the right Expression System
  • Bacterial vs. Mammalian Cell Lines
  • Pros and cons: production strategies for monoclonal antibodies
  • Evaluating hosts for optimal antibody yield
Purification Methods: Antigen Affinity Purification (Downstream)
  • Principles of antigen-affinity purification: selectivity and specificity
  • Technological advances in affinity media and ligand design
  • Integration into downstream processing: purity, yield and scalability
  • Optimization of purification processes for mAbs
Liquid Chromatography Mass Spectrometry (LCMS)
  •  LC-MS in mAbs characterization: sensitivity, specificity and throughput
  • Comparative analysis: when to use LBA vs. LC-MS
  • Glycosylation and its effect
Clinical Development Plan
  • Blueprint for success: mapping the clinical trial journey
  • Critical strategies for effective clinical development
  • Navigating clinical development stages – Phase I - III
Formulation strategies and stability testing for mAbs
  • Developability assessment and early formulation Screenings
  • Phase appropriate formulation strategies for mAbs
  • Conducting stability studies: protocols, parameters and analytical methods
ADC (Antibody Drug Conjugates) - Design and Application
  • The anatomy of ADCs: linkers, drugs and antibodies
  • Clinical applications of ADCs: successes and lessons learned
  • Future directions: innovations in linker chemistry and targeted delivery
Bi- and tri-specific Conjugates - Potential and Challenges
  • Designing bi- and tri-specific antibodies: concepts and constructs
  • Therapeutic potential: targeting complex diseases with multifunctional antibodies
  • Overcoming development challenges: manufacturing, stability and efficacy

ECA-Member*: € 1690,-
Non ECA Member*: € 1890,-
EU/GMP Inspectorates*: € 945,-
APIC Member Discount*: € 1790,-

Alle Preise zzgl. MwSt. Wichtige Hinweise zur Umsatzsteuer.

* auch unkompliziert per Kreditkarte bezahlbar
American Express Visa Mastercard

icon
Weitere Termine vor Ort
Weitere Termine vor Ort nicht verfügbar
icon
Weitere Termine online
Weitere Termine online nicht verfügbar
icon
Aufzeichnung nicht verfügbar

Haben Sie noch Fragen?

Wir stehen Ihnen für weitere Auskünfte gerne zur Verfügung.

Frau mit Headset
Tel.: +49 6221 84 44 0
E-Mail: info@concept-heidelberg.de

Zurück

Teilnehmerstimmen - das sagen andere über unsere Seminare:

"Die Umsetzung mit Memberspot ist wirklich ausgezeichnet gelungen.
Es unterstützt die Wissensvermittlung und gewährleistet auch die richtige Durchführung des Kurses.”
Christian Wagener, WAGENER & CO. GmbH
GMP Basis-Einstiegsschulung (B 1) - Aufzeichnung Online Seminar, April 2024

„Danke für das tolle und interessante Seminar! Ich nehme mir fachlich total viel mit und habe viele tolle Menschen kennengelernt.“
Melanie Schifferer, DAIICHI SANKYO EUROPE GmbH
Batch Record Review (QS 23)
September 2024

Guter, breit gefächerter Überblick mit interessanten Verknüpfungen zur Praxis,
welche die Theorie super veranschaulicht.”
Marina Kicoranovic, Labor Hartmann GmbH
GMP/Basis-Einstiegsschulung (B 14), September 2023

Die Referenten waren sehr gut! Sie haben sehr klar gesprochen, nur sehr wenige englische Begriffe
verwendet (super) und waren sehr praxisbezogen.”
Astrid Gießler, Regierungspräsidium Karlsruhe
Live Online Seminar - Basiskurs Computervalidierung & Datenintegrität im GxP Umfeld (B 3), Juni 2023

Sehr guter Bezug zur Schulung für einen GMP-Anfänger. Habe mich sehr gut abgeholt gefühlt.”
Dr. Harald Werner, Infraserv GmbH & Co. Höchst KG
GMP-Basisschulung (B 1), Juni 2023

„Interessante Themen, gut vorgetragen, die eigenen Erfahrungen der Vortragenden helfen, dies noch besser nachzuvollziehen.“ „Gute Gestaltung der Workshops, das Zusammenarbeiten in Gruppen und der Austausch mit anderen hilft sehr.“
Manuela Seibert, Merck, GMP-Leadauditor/in (FA 2), April 2024

NEWSLETTER

Bleiben Sie informiert mit dem GMP Newsletter von Concept Heidelberg!

GMP Newsletter

Concept Heidelberg bietet verschieden GMP Newsletter die Sie auf Ihren Bedarf hin zusammenstellen können.

Hier können Sie sich kostenfrei registrieren.

Kontakt

Kontaktieren Sie uns

Haben Sie Fragen?

Concept Heidelberg GmbH
Rischerstraße 8
69123 Heidelberg

Tel. :+49622184440
Fax : +49 6221 84 44 84
E-Mail: info@concept-heidelberg.de

zum Kontaktformular